Table 2

Summary of treatment response

Chemoimmunotherapy group (n=341)Radiomics analysis in chemoimmunotherapy groupChemotherapy group (n=57)
Training set
(n=174)
Validation set 1 (n=39)Validation set 2 (n=45)
ORR77.4%70.1%84.6%88.9%73.7%
DCR97.4%96.6%92.3%100.0%89.5%
Death25.5%26.4%43.6%4.4%42.1%
Follow-up time,
median (95% CI), months
12.1 (11.0 to 13.2)12.4 (11.1 to 13.7)15.3 (13.6 to 16.9)7.1 (6.0 to 8.2)11.8 (8.9 to 14.7)
PFS, median (95% CI), months7.1 (6.6 to 7.7)6.9 (6.2 to 7.7)6.9 (4.7 to 9.2)8.1 (6.3 to 9.9)5.9 (5.1 to 6.7)
OS, median (95% CI), monthsNRNR19.1 (9.9 to 28.3)NR13.7 (8.9 to 18.5)
6-month PFS (%)60.7%60.3%53.8%66.1%45.5%
9-month PFS (%)38.2%36.0%41.0%44.4%13.0%
12-month PFS (%)28.3%25.6%38.3%22.4%4.3%
12-month OS (%)75.0%73.2%62.6%86.4%59.1%
18-month OS (%)58.5%60.7%51.6%86.4%30.8%
  • DCR, disease control rate; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.